Kindeva Drug Delivery Investing in Greener Manufacturing Practices

Kindeva Drug Delivery (Kindeva) is investing in a second manufacturing line to produce pressurized metered-dose inhaler (pMDI) products containing low-GWP (global warming potential) propellants in its Loughborough, U.K., facility.
 
The new line will be capable of handling both HFA-152a and HFO-1234ze propellants—which have a 90% and 99.9% GWP lower than the industry standard HFA-134a (respectively)—and is expected to be operational in 2026. Kindeva’s first pMDI manufacturing line, announced in 2022, is in its installation phase and will be completed later in 2024.
 
“This investment will bring to the market one of the first large-volume commercial green propellant lines to the contract manufacturing market capable of supplying up to 50 million pMDI units per year,” Kideva CEO Milton Boyer said. “This second investment in low-GWP GMP manufacturing capacity further underscores Kindeva’s commitment to enable the industry to meet its sustainability goals, whilst ensuring patient choice is not compromised. With our first GMP low-GWP manufacturing line expected to be operational in 2024, we are proud to be leading the transition to low-GWP propellants by ensuring the capacity is available.” 
 
The new manufacturing line meets an increased customer demand for more sustainable pMDI products and considers the recent adoption of F-gas legislation in the European Union. Phase down of the existing propellants will begin in 2027 in the European Union and be completed by the end of 2029. 
 
“With a track record of nearly 70 years in pMDIs—including the invention of the pMDI in 1956 and leading the CFC- to HFA-inhaler transition in the 1990s—we are excited to be a part of this industry-wide switch in the pMDI space,” Boyer continued. “Kindeva is doing everything we can to ensure a greener future for all stakeholders by doubling down on our commitment to the low-GWP evolution.”

Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. It develops and manufactures products across various drug-delivery formats, including pulmonary and nasal; injectable; and transdermal. The firm’s service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from its manufacturing, research, and development facilities in the United States and United Kingdom.